TITLE

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo

PUB. DATE
December 2009
SOURCE
International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p133
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This Phase IIa trial conducted by Kremer et al. found that CP-690,550, the inhibitor of the JAK1/3 Janus tyrosine kinases, administrated at dosages of 5 mg, 15 mg, or 30 mg twice daily, was efficacious for all primary and secondary endpoint measures in the treatment of patients with active rheumatoid arthritis.
ACCESSION #
48381932

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics